Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering

Actuate Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of approximately 30.99 million shares of common stock and 15.49 million warrants at $0.71 per share-warrant set. The offering is expected to raise approximately $11.0 million in gross proceeds, with potential additional proceeds of $7.0 million if warrants are fully exercised. The company plans to use net proceeds for working capital and general corporate purposes.